Richard Chin
Founder and CEO

Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of success in the biopharmaceutical industry, including almost a dozen drug approvals and over 50 INDs.

 

Drugs Richard developed, including Lucentis®, Xolair®, Tysabri®, and Rituxan® for immune diseases, have current aggregate sales of well over $10 billion per year.

​

Most recently, Richard was the Founder and CEO of KindredBio (NASDAQ:KIN), a veterinary biotech company he founded, took public, and sold to Elanco for $440 million.

​

Previously, Richard was CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries; CEO of Oxigene, a NASDAQ-listed biotechnology company; Senior Vice President of Global Development at Elan; and Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw approximately half of Genentech’s clinical programs.

​

Richard was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs in the United States. He has authored several textbooks on clinical development and previously taught drug development at UCSF School of Medicine. Richard has trained over a dozen clinical trialists who have become Chief Medical Officers and Chief Executive Officers at biotech companies across the industry.

​